SAB Biotherapeutics Inc.

NASDAQ: SABS · Real-Time Price · USD
2.10
-0.08 (-3.67%)
At close: Aug 19, 2025, 11:51 AM

SAB Biotherapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-34.11M -42.19M -17.14M -17.14M
Depreciation & Amortization
4.79M 3.75M 3.29M 1.65M
Stock-Based Compensation
2.94M 2.42M 2.67M 2.31M
Other Working Capital
-3.17M -528.64K 3.83M 2.06M
Other Non-Cash Items
-5.62M 8.58M 1.48M 3.48M
Deferred Income Tax
n/a n/a n/a n/a
Change in Working Capital
-2.3M 2.33M 13.45M 13.45M
Operating Cash Flow
-34.29M -25.12M 3.76M 3.76M
Capital Expenditures
-337.26K -197.15K -10.94M -10.94M
Cash Acquisitions
n/a 44.45K 76.39K n/a
Purchase of Investments
-37.45M n/a n/a n/a
Sales Maturities Of Investments
25.82M n/a n/a n/a
Other Investing Acitivies
n/a n/a -76.39K n/a
Investing Cash Flow
-11.96M -152.7K -10.94M -10.94M
Debt Repayment
-907K -390.44K -1.19M 1.54M
Common Stock Repurchased
n/a n/a -5.52M n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
-286.04K 59.66M 76.97K 32.57M
Financial Cash Flow
-1.17M 66.77M 1.05M 34.12M
Net Cash Flow
-47.67M 41.52M 26.93M 26.93M
Free Cash Flow
-34.63M -25.32M -7.19M -7.19M